Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study

BACKGROUND: Our retrospective, international study aimed at evaluating the activity and safety of eribulin mesylate (EM) in pretreated metastatic breast cancer (MBC) in a routine clinical setting. METHODS: Patients treated with EM for a locally advanced or MBC between March 2011 and January 2014 wer...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMC Cancer
Auteurs principaux: Dell’Ova, Mélodie, De Maio, Eléonora, Guiu, Séverine, Roca, Lise, Dalenc, Florence, Durigova, Anna, Pinguet, Frédéric, Bekhtari, Khedidja, Jacot, William, Pouderoux, Stéphane
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2015
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4599752/
https://ncbi.nlm.nih.gov/pubmed/26449988
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1673-3
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires